虚血再灌流障害:パイプラインレビュー2019下半期

【英語タイトル】Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120323)・商品コード:GDATA9120323
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:173
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Ischemia Reperfusion Injury – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury – Pipeline Review, H2 2019, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 35 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ischemia Reperfusion Injury – Overview
Ischemia Reperfusion Injury – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ischemia Reperfusion Injury – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ischemia Reperfusion Injury – Companies Involved in Therapeutics Development
Akashi Therapeutics Inc
Argenx SE
Balmes Transplantation SAS
Bolder Biotechnology Inc
Catalyst Biosciences Inc
Celdara Medical LLC
Cellmid Ltd
CFM Pharma Holding BV
Corline Biomedical AB
Cypralis Ltd
Gilead Sciences Inc
Glucox Biotech AB
Ischemix Inc
Lee’s Pharmaceutical Holdings Ltd
LG Chem Ltd
Mallinckrodt Plc
Orion Corp
Pfizer Inc
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
SBI Pharmaceuticals Co Ltd
Stealth BioTherapeutics Corp
United Therapeutics Corp
Ischemia Reperfusion Injury – Drug Profiles
aminolevulinic acid hydrochloride – Drug Profile
ANV-6L15 – Drug Profile
AP-39 – Drug Profile
APP-103 – Drug Profile
ARGX-117 – Drug Profile
AT-300 – Drug Profile
BBT-059 – Drug Profile
BT-0213 – Drug Profile
BT-0301 – Drug Profile
BT-0402 – Drug Profile
CAB-101 – Drug Profile
cannabidiol – Drug Profile
CB-2782 – Drug Profile
CC-4066 – Drug Profile
cerium oxide – Drug Profile
CMX-2043 – Drug Profile
cyclocreatine phosphate – Drug Profile
Cymac-001 – Drug Profile
DH-404 – Drug Profile
Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis – Drug Profile
IL-233 – Drug Profile
KN-93 – Drug Profile
LC-280126 – Drug Profile
MG-53 – Drug Profile
Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock – Drug Profile
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury – Drug Profile
MP-3964 – Drug Profile
NLS-3 – Drug Profile
NP-202 – Drug Profile
Oligonucleotide for Cardiovascular Diseases and Oncology – Drug Profile
ORM-10103 – Drug Profile
PEG-HCC – Drug Profile
Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury – Drug Profile
R-100 – Drug Profile
R-190 – Drug Profile
Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders – Drug Profile
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis – Drug Profile
Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis – Drug Profile
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia – Drug Profile
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury – Drug Profile
regadenoson – Drug Profile
Remodulin – Drug Profile
Renaparin – Drug Profile
SBT-20 – Drug Profile
SBT-272 – Drug Profile
sirolimus – Drug Profile
Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury – Drug Profile
Small Molecules for Ischemia Reperfusion Injury – Drug Profile
Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation – Drug Profile
Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury – Drug Profile
Small Molecules for Myocardial Ischemia Reperfusion Injury – Drug Profile
Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury – Drug Profile
Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury – Drug Profile
Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury – Drug Profile
Synthetic Peptide for Ischemia Reperfusion Injury – Drug Profile
Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology – Drug Profile
Ti-061 – Drug Profile
tiomolibdate diammonium – Drug Profile
tiprelestat – Drug Profile
tofacitinib citrate – Drug Profile
UWA-TAT – Drug Profile
Vanadis-01 – Drug Profile
Vanadis-03 – Drug Profile
VCP-746 – Drug Profile
YQ-23 – Drug Profile
ZK-001 – Drug Profile
Ischemia Reperfusion Injury – Dormant Projects
Ischemia Reperfusion Injury – Discontinued Products
Ischemia Reperfusion Injury – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Ischemia Reperfusion Injury - Pipeline by Akashi Therapeutics Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Argenx SE, H2 2019
Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, H2 2019
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, H2 2019
Ischemia Reperfusion Injury - Pipeline by Cellmid Ltd, H2 2019
Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, H2 2019
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2019
Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, H2 2019
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2019
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
Ischemia Reperfusion Injury - Pipeline by LG Chem Ltd, H2 2019
Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Orion Corp, H2 2019
Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2019
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2019
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, H2 2019
Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, H2 2019
Ischemia Reperfusion Injury - Dormant Projects, H2 2019
Ischemia Reperfusion Injury - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Ischemia Reperfusion Injury, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

【掲載企業】

Akashi Therapeutics Inc
Argenx SE
Balmes Transplantation SAS
Bolder Biotechnology Inc
Catalyst Biosciences Inc
Celdara Medical LLC
Cellmid Ltd
CFM Pharma Holding BV
Corline Biomedical AB
Cypralis Ltd
Gilead Sciences Inc
Glucox Biotech AB
Ischemix Inc
Lee's Pharmaceutical Holdings Ltd
LG Chem Ltd
Mallinckrodt Plc
Orion Corp
Pfizer Inc
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
SBI Pharmaceuticals Co Ltd
Stealth BioTherapeutics Corp
United Therapeutics Corp

★調査レポート[虚血再灌流障害:パイプラインレビュー2019下半期] (コード:GDATA9120323)販売に関する免責事項を必ずご確認ください。
★調査レポート[虚血再灌流障害:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆